Rapid clearance of virus after acute HIV-1 infection: Correlates of risk of AIDS

Journal of Infectious Diseases

Volumn 189, Issue 10, 2004, Pages 1793-1801

  Blattner, William A ^a   Oursler, Kris Ann ^a   Cleghorn, Farley ^a   Charurat, Manhattan ^a   Sill, Anne ^a   Bartholomew, Courtenay ^c   Jack, Noreen ^c   O'Brien, Thomas ^b   Edwards, Jeffrey ^c   Tomaras, Georgia ^d   Weinhold, Kent ^d   Greenberg, Michael ^d  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Medical Research Foundation of Trinidad and Tobago   (Trinidad and Tobago)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; KAPLAN MEIER METHOD; LINEAR REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MALE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; STEADY STATE; VIREMIA; VIRUS IDENTIFICATION; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 2442707600     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/386306     Document Type: Article

References (55)

1. Craib KJ, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Infect Dis 1997; 176:798-800.
2. +T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. J Acquir Immune Defic Syndr 1999; 22:437-44.
3. Lefrere JJ, Roudot-Thoraval F, Mariotti M, et al. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 1998; 177:1541-8.
4. Vanhems P, Hirschel B, Phillips AN, et al. Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis 2000; 182:334-7.
5. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
6. Schacker T, Little S, Connick E, et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000; 181:354-7.
7. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-I infection. J Exp Med 1999; 190:841-50.
8. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-20.
9. Vanhems P, Allard R, Cooper DA. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998; 26:323-9.
10. + and redistribution of CCR5-CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection. J Infect Dis 2001; 183:736-43.
11. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277:959-65.
12. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort. Science 1998; 279:389-93.
13. + T cells. Science 1995; 270:1811-5.
14. Ullum H, Cozzi LA, Victor J, et al. Production of β-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1β are associated with a decreased risk of HIV disease progression. J Infect Dis 1998; 177:331-6.
15. Ferbas J, Giorgi JV, Amini S, et al. Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1α, and MIP-1β in vitro is a correlate of reduced human immunodeficiency virus burden in vivo. J Infect Dis 2000; 182:1247-50.
16. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283-98.
17. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17):1-19.
18. Daar ES. Virology and immunology of acute HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S229-34.
19. Lifson JD, Nowak MA, Goldstein S, et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997; 71:9508-14.
20. Schacker T, Little S, Connick E, et al. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis 2001; 183:555-62.
21. + T cells. Science 1999; 286:1353-7.
22. Gange SJ, Munoz A, Chmiel JS, et al. Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS. Proc Natl Acad Sci USA 1998; 95:10848-53.
23. + lymphocyte count: implications for AIDS pathogenesis. Clin Immunol Immunopathol 1998; 88:256-63.
24. Lindback S, Karlsson AC, Mittler J, et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 2000; 14:2283-91.
25. Mellors JW, Kingsley LA, Rinaldo C, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
26. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:155-61.
27. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995; 274:554-8.
28. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-10.
29. Blattner W, Jack N, Sill A, et al. HIV vaccine trial preparedness in a high risk clade B heterosexual cohort in Trinidad and Tobago [abstract WePeA4107]. In: Program and abstracts of the XIV International AIDS Conference (2000). Stockholm: International AIDS Society, 2000.
30. Rosenberg PS, Goedert J, Biggar RJ. Effect of age at seroconversion on the natural AIDS incubation distribution. Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters. AIDS 1994; 8:803-10.
31. Prins JM, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS 1997; 11:621-31.
32. Biggar RJ. AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters. AIDS 1990; 4:1059-66.
33. Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS 2000; 14:123-31.
34. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-80.
35. Sabin CA, Devereux H, Phillips AN, et al. Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23:172-7.
36. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-90.
37. Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-8.
38. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. CytotoxicT-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
39. Price DA, O'Callaghan CA, Whelan JA, Easterbrook PJ, Phillips RE. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection. Clin Sci (Lond) 1999; 97:707-18.
40. + T cell mediated noncytolytic inhibition of human immunodeficiency virus type I. Front Biosci 2001; 6: D575-98.
41. Vidai C, Garcia F, Romeu J, et al. Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. AIDS 1998; 12:1285-9.
42. Wilson JD, Ogg GS, Allen RL, et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 2000; 14:225-33.
43. Letvin NL, Schmitz JE, Jordan HL, et al. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol Rev 1999; 170:127-34.
44. Markham RB, Wang WC, Weisstein AE, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci USA 1998; 95:12568-73.
45. O'Connor DH, Allen TM, Vogel TU, et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-9.
46. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
47. Villinger F, Folks TM, Lauro S, et al. Immunological and virological studies of natural SIV infection of disease-resistant nonhuman primates. Immunol Lett 1996; 51:59-68.
48. Chakrabarti LA, Lewin SR, Zhang L, et al. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol 2000; 74:1209-23.
49. Wallace M, Waterman PM, Mitchen JL, et al. Lymphocyte activation during acute simian/human immunodeficiency virus SHIV(89.6PD) infection in macaques. J Virol 1999; 73:10236-44.
50. Diop OM, Gueye A, Dias-Tavares M, et al. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 2000; 74:7538-47.
51. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83-92.
52. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998; 178:1279-87.
53. + T-cell losses using adjusted correlative analyses. AIDS 2000; 14:951-8.
54. + lymphocytes per microliter. AIDS Res Hum Retroviruses 1999; 15:1419-25.
55. Khatissian E, Chakrabarti L, Hurtrel B. Cytokine patterns and viral load in lymph nodes during the early stages of SIV infection. Res Virol 1996; 147:181-9.